The UM CURE 2020 Approach

The centre of our approach is to characterise the tumour tissue from UM patients with metastases, in order to define actionable therapeutic targets.

 

The pharmaceutical industry mainly focuses
 on developing drugs which may work in as
 many tumour types as possible: 
this approach only rarely results in drugs that
 work in rare tumours, such as UM. While
 our major objective is to identify new
 potential therapeutic strategies for metastatic
 UM, the centre of our approach is to characterise the tumour tissue from UM patients with metastases, in order to define actionable targets.

We will develop tumour-specific preclinical models and biomarkers to evaluate single drugs or their combinations. The most promising drugs will then be tested in clinical trials, outside the frame of the project. In addition, we aim at connecting directly with UM patients throughout Europe, providing them with up-to-date information on new treatments for their disease and possibilities to get involved. Patients are therefore central in each of our research steps up until the dissemination and implementation of the results.